Regulation of IL-13 transcription in human T-cells by GATA-3/NF-AT complexes: modulation by corticosteroids

每12个英国人中就有1人患有哮喘，目前有520万人正在接受治疗。英国是欧洲年轻人哮喘患病率最高的国家之一，报告哮喘症状的儿童人数在过去30年里增加了6倍。哮喘每年花费NHS 8.89亿英镑，据估计，每年因哮喘损失至少1270万个工作日。因此，过敏性疾病发病率的上升和随之而来的保健费用是主要的健康和社会经济问题。大多数哮喘患者对吸入皮质类固醇治疗有反应，尽管其作用机制尚不清楚。我们希望确定皮质类固醇如何降低哮喘相关关键蛋白的表达，特别是炎症介质白细胞介素13 （IL-13）。了解皮质类固醇如何在轻度哮喘中起作用可能有助于开发针对这些过程的新药，这些药物的副作用更少，并且可能能够治疗皮质类固醇不能改善的严重哮喘患者。这将改善病人的护理，减少副作用，并为NHS节省成本，

Asthma affects 1 in 12 of the UK population, with 5.2 million people currently receiving treatment. The UK has one of the highest prevalence of asthma in young adults in Europe and the numbers of children reporting asthma symptoms has risen six fold over the last 30 years. Asthma costs the NHS #889m per year and it is estimated that at least 12.7 million working days are lost due to asthma each year. The rising prevalence of allergic diseases and accompanying health care costs are therefore major health and socio-economic problems. Most asthmatic subjects respond to treatment with inhaled corticosteroids although the mechanisms underlying their action are not clear. We wish to determine how corticosteroids reduce the expression of key proteins involved in asthma particularly the inflammatory mediator interleukin 13 (IL-13). Understanding how corticosteroids work in mild asthma may help to develop new drugs to target these processes that have fewer side-effects and may be able to treat patients with severe asthma who do not improve with corticosteroids. This will result in improved patient care with less side-effects and in cost savings to the NHS,